Adalimumab dose intensification in hidradenitis suppurativa: effectiveness and safety results of a multicenter study

2021 ◽  
Author(s):  
E.M. Sánchez Martínez ◽  
G. Murray ◽  
F. Alfageme Roldán ◽  
R. García Ruiz ◽  
A.M. Tobin ◽  
...  
Keyword(s):  
Multicenter Study ◽  
Hidradenitis Suppurativa ◽  
Dose Intensification

The clinical, biochemical, and ultrasonographic characteristics of patients with hidradenitis suppurativa in Northern Peninsular Malaysia: a multicenter study

2018 ◽  
Vol 57 (12) ◽  
pp. 1454-1463 ◽  
Author(s):  
Chai Har Loo ◽  
Wooi Chiang Tan ◽  
Jyh Jong Tang ◽  
Yek Huan Khor ◽  
Manimala T. Manikam ◽  
...  
Keyword(s):  
Multicenter Study ◽  
Hidradenitis Suppurativa ◽  
Peninsular Malaysia

Clinical characteristics of pediatric hidradenitis suppurativa: a cross-sectional multicenter study of 140 patients

2020 ◽  
Vol 312 (10) ◽  
pp. 715-724 ◽  
Author(s):  
Peter Theut Riis ◽  
Ditte Marie Saunte ◽  
Viktoria Sigsgaard ◽  
Axel Patrice Villani ◽  
Philippe Guillem ◽  
...  
Keyword(s):  
Multicenter Study ◽  
Hidradenitis Suppurativa ◽  
Clinical Characteristics ◽  
Cross Sectional

Adalimumab Dose Intensification in Recalcitrant Hidradenitis Suppurativa/Acne Inversa

Dermatology ◽  
2019 ◽  
Vol 236 (1) ◽  
pp. 25-30 ◽  
Author(s):  
Christos C. Zouboulis ◽  
Hendrik Hansen ◽  
Raffaele Dante Caposiena Caro ◽  
Giovanni Damiani ◽  
Isabelle Delorme ◽  
...  
Keyword(s):  
Hidradenitis Suppurativa ◽  
Life Quality ◽  
Case Series ◽  
Young Female ◽  
Acne Inversa ◽  
Physician Global Assessment ◽  
Dose Intensification ◽  
Score System ◽  
Short And Long Term

Background: Adalimumab is the only approved compound for the treatment of adult patients with moderate-to-severe hidradenitis suppurativa (HS) who did not respond to a systemic classical treatment. Despite its significant short- and long-term efficacy, a percentage of patients do not respond sufficiently. Moreover, some primary responders experience a response loss with time. Objective: To analyse the effectiveness of adalimumab dose intensification in HS patients. Methods: A case series of adalimumab 80 mg/week subcutaneously (s.c.) compassionate use in patients with HS, who did not respond sufficiently or in primary responders with progressive response loss to the registered adalimumab dose of 40 mg/week s.c. Patients were collected and evaluated retrospectively. Patients’ data were extracted from medical records. Results: The 14 patients collected were Caucasian with HS of Hurley stage II–III and moderate or severe International HS Severity Score System (IHS4) stage. Adalimumab dose intensification significantly improved IHS4 score, Pain Index, HS-Physician Global Assessment, pain, and Cardiff Dermatology Life Quality Index. Two young female patients with HS and Crohn’s disease developed psoriatic lesions during the treatment with adalimumab 80 mg/week s.c. Conclusion: An enhanced level of effectiveness was assessed in the majority of the HS patients treated with adalimumab dose intensification (80 mg/week s.c.). Larger studies are required to evaluate this observation.

scholarly journals Patients with hidradenitis suppurativa may suffer from neuropathic pain: A Finnish multicenter study

2020 ◽  
Vol 82 (5) ◽  
pp. 1232-1234 ◽  
Author(s):  
Laura Huilaja ◽  
Mirkka J. Hirvonen ◽  
Tiina Lipitsä ◽  
Armi Vihervaara ◽  
Rauno Harvima ◽  
...  
Keyword(s):  
Neuropathic Pain ◽  
Multicenter Study ◽  
Hidradenitis Suppurativa
Sign in / Sign up

Export Citation Format

Share Document